Guardant Health, Inc. (NASDAQ:GH) Holdings Raised by D.A. Davidson & CO.

D.A. Davidson & CO. increased its holdings in shares of Guardant Health, Inc. (NASDAQ:GHFree Report) by 12.2% during the 3rd quarter, Holdings Channel.com reports. The fund owned 24,225 shares of the company’s stock after acquiring an additional 2,630 shares during the period. D.A. Davidson & CO.’s holdings in Guardant Health were worth $718,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Guardant Health by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 8,915,566 shares of the company’s stock worth $479,925,000 after buying an additional 74,247 shares during the period. Capital International Investors grew its position in shares of Guardant Health by 71.0% during the 1st quarter. Capital International Investors now owns 5,081,624 shares of the company’s stock worth $336,607,000 after buying an additional 2,110,240 shares during the period. Alliancebernstein L.P. grew its position in shares of Guardant Health by 35.2% during the 2nd quarter. Alliancebernstein L.P. now owns 4,463,669 shares of the company’s stock worth $159,799,000 after buying an additional 1,161,901 shares during the period. Eventide Asset Management LLC grew its position in shares of Guardant Health by 113.8% during the 2nd quarter. Eventide Asset Management LLC now owns 4,008,602 shares of the company’s stock worth $143,508,000 after buying an additional 2,133,582 shares during the period. Finally, Temasek Holdings Private Ltd grew its position in shares of Guardant Health by 8.2% during the 2nd quarter. Temasek Holdings Private Ltd now owns 3,963,872 shares of the company’s stock worth $141,907,000 after buying an additional 299,510 shares during the period. 92.65% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Kumud Kalia sold 5,800 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $26.37, for a total transaction of $152,946.00. Following the completion of the transaction, the insider now owns 5,926 shares in the company, valued at $156,268.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GH shares. The Goldman Sachs Group decreased their price objective on shares of Guardant Health from $43.00 to $37.00 and set a “buy” rating for the company in a report on Monday, January 29th. Raymond James upgraded shares of Guardant Health from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a report on Monday, November 13th. Morgan Stanley decreased their price objective on shares of Guardant Health from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Wednesday, November 8th. Guggenheim started coverage on shares of Guardant Health in a report on Thursday, December 14th. They set a “neutral” rating for the company. Finally, Wolfe Research started coverage on shares of Guardant Health in a report on Wednesday, December 13th. They set a “peer perform” rating for the company. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $48.00.

Read Our Latest Stock Report on GH

Guardant Health Stock Performance

Shares of GH stock opened at $23.23 on Tuesday. Guardant Health, Inc. has a 12 month low of $20.67 and a 12 month high of $41.06. The company’s fifty day simple moving average is $25.15 and its 200-day simple moving average is $28.28. The firm has a market cap of $2.74 billion, a PE ratio of -5.72 and a beta of 0.99. The company has a quick ratio of 5.60, a current ratio of 5.94 and a debt-to-equity ratio of 4.99.

Guardant Health Company Profile

(Free Report)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Featured Stories

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GHFree Report).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.